Red Flag Diagnostics GmbH operates as a holding company, which engages in the development and sale of tests for the diagnosis of tuberculosis. The company was founded on December 14, 2009 and is headquartered in Saarbruecken, Germany.

Amedeo Nappi SpA operates as a chemical company. It specializes in production of waxes, paraffins, microcristalline, emulsions, and special blends. The company was founded in 1967 and is headquartered in Liveri, Italy.

Lophius Biosciences is a young biotechnology company developing innovative products for the diagnosis of acute infectious and autoimmune diseases. The company is also offering custom-made services in the area of cell based bioactivity and quality tests for pharmaceutical agents. The core competencies of Lophius Biosciences are in the area of Immunology and T-cell diagnostics. Lophius Biosciences is a privately-held German biotechnology company focusing on the development and marketing of innovative immune diagnostic systems to improve therapy control and personalized treatment of patients in the area of transplantation, infectious and autoimmune diseases. The company’s developments are based on its expertise in cell-mediated immunity as well as on its proprietary T-activation® and Reverse T Cell Technology platforms. Whereas the T-activation® technology platform allows an efficient stimulation of a broad spectrum of clinically-relevant immune effector cells to accurately measure the cell-mediated immunity, the Reverse T Cell Technology platform can distinguish between active and memory T cells to develop innovative diagnostics.

Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies are widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

ALK is a global research-driven pharmaceutical company that focuses on prevention, diagnosis and treatment of allergies. Since 1923 ALK has been working to improve the quality of life for allergy patients by developing drugs that target the cause of allergy. ALK is the world leader in allergy immunotherapy - a unique treatment of the cause of allergies. The treatment induces a protective immune response that provides a sustained reduction of allergy symptoms and reduces the risk of developing asthma. ALK provides allergy immunotherapy products as injections, sublingual drops and sublingual tablets, which is the newest, best documented and most convenient treatment for patients. The portfolio of products also includes an adrenaline used to treat severe allergic reactions (anaphylactic shock). ALK invests annually approx. 20% of revenue in research that aims to develop new, evidence-based allergy immunotherapy. Research and development pipeline includes sublingual allergy immunoterapy tablets against ragweed, house dust mite and tree pollen allergy. ALK has signed partnership agreements with Merck and Torii Pharmaceutical, concerning the development, registration and commercialisation of tablets in Northern America and Japan. ALK has approx. 1,800 employees with subsidiaries, production facilities and distributors worldwide. The company headquarters is in Denmark and is listed on NASDAQ OMX Copenhagen (OMX: ALK B). In 2013 the turnover was more than DKK 2.2 billion (EURm 300).

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

ALK is a healthcare service provider. They offer products and services via a web shop to help people manage their allergies. It also provides treatment for respiratory allergies that works by treating the underlying cause of the allergy.

Kangwanda offers research and development services for tumor immune-related technologies. It provides immune cell therapy and immune checkpoint antibodies. It has a research and development center with a functional cytology laboratory and an experimental animal room.

Chongqing Zhifei Biological Products Co., Ltd. engages in the wholesale of biological products and vaccines. Its main products are meningococcal group A&C conjugate vaccine, meningococcal polysaccharide vaccine, mycobacterium vaccae, Haemophilus Influenzae type b conjugate vaccine, and freeze-dried live attenuated hepatitis A vaccine. Its other activities are biotechnology research, development, and consulting; import and export, and storage services. The company was founded on July 20, 1995 and is headquartered in Chongqing, China.

The American Can Company was a manufacturer of tin cans. It was a member of the Tin Can Trust, that controlled a "large percentage of business in the United States in tin cans, containers, and packages of tin." American Can Company ranked 97th among United States corporations in the value of World War II military production contracts. It was formerly a member of the Dow Jones Industrial Average from 1959–1991, though after 1987 it had renamed itself Primerica, a financial conglomerate which had divested itself of its packaging arm in 1986.

Guangzhou Xinji Biomedical Research Institute Co., Ltd., established on 2020-09-13, Business scope includes medical research and experimental development;Biochemical product technology research and development;R&D and application of cell technology;Information Technology Consulting Services;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;;Drug retail;Drug Wholesale;pharmaceutical production;Import and export;Technology Import and Export;

Beijing Xiangrui Biological Products Co., Ltd., established on 2000-03-24, Business scope includes production,Sales of small volume injections[vaccine(ACmeningococcal conjugate vaccine),In Vivo Diagnostic Reagents(Tuberculin pure protein derivative,BCG Pure Protein Derivatives)];Sales of Class III Medical Devices;Production of Class III medical devices(Production of in vitro diagnostic reagents);biotechnology development,consult,transfer;Import and export,Technology Import and Export,Agent import and export;SalesI,IIclass of medical devices.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Production of Class III medical devices(Production of in vitro diagnostic reagents)and items that are legally subject to approval,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Astrimmune Ltd. is a British private company located in Mansfield. The firm develops fluid-flow cell-Imaging for cancer monitoring. It was founded in 2011.

Beijing Zhifei Green Bamboo Bio-Pharmaceutical Co., Ltd., established on 2003-10-08, The scope of business includes the production of vaccines;Dedicated transport of goods(Refrigerated)(The road transport business license is valid until2024year08moon19day);Biological product,medicine,Diagnostic reagents,Technology development of medical devices,technology transfer,Technical Training,Technical Services;Biotechnology Information Consulting;Sales of laboratory immunological reagents,laboratory apparatus;Import and export,Technology Import and Export.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Chengdu Keen Biological Technology Co., Ltd. is a company headquartered in Chengdu, China, that engages in research and development of tuberculosis diagnostic biological products and therapeutic vaccines. It was founded in 2018.